Literature DB >> 10844492

Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody.

C M Owen1, P V Harrison.   

Abstract

T-cell mediated inflammation plays an important role in the aetiology of psoriasis. We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect(R) Novartis Pharmaceuticals UK Ltd), an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10844492     DOI： 10.1046/j.1365-2230.2000.00612.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


  8 in total

Review 1.  Disease mechanisms in psoriasis and psoriatic arthritis.

Authors:  P Costello; O FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

2.  [Psoriasis therapy with biologicals].

Authors:  U Mrowietz
Journal:  Hautarzt       Date:  2003-02-11       Impact factor: 0.751

Review 3.  Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.

Authors:  Ya-Chu Tsai; Tsen-Fang Tsai
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-11-06       Impact factor: 5.346

Review 4.  Targeted immunotherapy trials for idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

5.  TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis.

Authors:  Honglin Wang; Thorsten Peters; Anca Sindrilaru; Daniel Kess; Tsvetelina Oreshkova; Xue-Zhong Yu; Anne Maria Seier; Heike Schreiber; Meinhard Wlaschek; Robert Blakytny; Jan Röhrbein; Guido Schulz; Johannes M Weiss; Karin Scharffetter-Kochanek
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 6.  Use of biologic agents in combination with other therapies for the treatment of psoriasis.

Authors:  Jennifer C Cather; Jeffrey J Crowley
Journal:  Am J Clin Dermatol       Date:  2014-12       Impact factor: 7.403

7.  Novel immunobiologics for psoriasis.

Authors:  Nilanjan Ghosh; P N Singh; Vikas Kumar
Journal:  Indian J Pharmacol       Date:  2008-06       Impact factor: 1.200

8.  Biologics in dermatologic therapy - an update.

Authors:  Arijit Coondoo
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.